MeSH term
Frequency | Condition_Probility | Adult | 17 | 0.0 |
Aged | 16 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Combined Modality Therapy | 4 | 0.0 |
Comparative Study | 13 | 0.0 |
Female | 36 | 0.0 |
Gastrectomy | 2 | 3.0 |
Humans | 75 | 0.0 |
Lymphatic Metastasis | 4 | 0.0 |
Male | 32 | 0.0 |
Middle Aged | 23 | 0.0 |
Postoperative Care | 3 | 4.0 |
Research Support, Non-U.S. Gov't | 22 | 0.0 |
Survival Rate | 2 | 0.0 |
Mitomycin/*therapeutic use | 2 | 25.0 |
Neoplasm Staging | 2 | 0.0 |
Phenotype | 3 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 12 | 1.0 |
Doxorubicin/pharmacology | 4 | 1.0 |
English Abstract | 27 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Fluorouracil/pharmacology | 3 | 5.0 |
Methotrexate/pharmacology | 2 | 2.0 |
Mitomycin/pharmacology | 5 | 5.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality | 2 | 25.0 |
Cisplatin/administration & dosage/adverse effects | 2 | 8.0 |
Lung Neoplasms/*drug therapy/mortality | 2 | 22.0 |
Mitomycin/administration & dosage/adverse effects | 2 | 50.0 |
Vindesine/administration & dosage/adverse effects | 2 | 100.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 13 | 2.0 |
Colorectal Neoplasms/*pathology | 2 | 3.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Mitomycin/administration & dosage | 8 | 20.0 |
*Cell Cycle Proteins | 3 | 0.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Mitomycin/*pharmacology | 4 | 16.0 |
Prognosis | 4 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Carcinoma, Squamous Cell/*pathology | 2 | 2.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Drug Synergism | 6 | 0.0 |
Transfection | 3 | 0.0 |
Drug Screening Assays, Antitumor | 10 | 2.0 |
Mitomycin/toxicity | 2 | 22.0 |
Diagnosis, Differential | 2 | 0.0 |
Animals | 24 | 0.0 |
Swine | 2 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Mice | 19 | 0.0 |
Mice, Nude | 8 | 0.0 |
Neoplasm Transplantation | 8 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Rats | 2 | 0.0 |
Camptothecin/administration & dosage/analogs & derivatives | 2 | 40.0 |
Cisplatin/administration & dosage | 8 | 3.0 |
Drug Administration Schedule | 5 | 0.0 |
Fluorouracil/administration & dosage | 7 | 5.0 |
Adolescent | 4 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Child | 4 | 0.0 |
Gamma Rays | 4 | 1.0 |
Time Factors | 4 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Fanconi Anemia/*genetics | 5 | 10.0 |
*Nuclear Proteins | 2 | 0.0 |
Bleomycin/administration & dosage | 3 | 4.0 |
Carcinoma, Squamous Cell/*drug therapy/pathology | 2 | 20.0 |
Radiation Injuries/*etiology | 2 | 50.0 |
Radiotherapy Dosage | 2 | 1.0 |
Prospective Studies | 2 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
DNA/biosynthesis | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 7 | 0.0 |
Base Sequence | 2 | 0.0 |
Molecular Sequence Data | 2 | 0.0 |
Cell Line | 6 | 0.0 |
Drug Resistance | 4 | 0.0 |
Lung Neoplasms | 3 | 2.0 |
NAD(P)H Dehydrogenase (Quinone)/metabolism | 2 | 7.0 |
Dogs | 2 | 0.0 |
Drug Interactions | 2 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Bleomycin/pharmacology | 2 | 7.0 |
*DNA Damage | 4 | 0.0 |
Proto-Oncogene Proteins c-bcl-2 | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage | 3 | 5.0 |
Infusions, Intra-Arterial | 3 | 4.0 |
Adenocarcinoma/drug therapy | 2 | 15.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cell Survival/*drug effects | 2 | 2.0 |
Colonic Neoplasms | 2 | 1.0 |
DNA, Neoplasm/drug effects/radiation effects | 2 | 50.0 |
KB Cells | 2 | 2.0 |
Melanoma, Experimental | 2 | 10.0 |
Mitomycins/pharmacology | 6 | 20.0 |
Antineoplastic Combined Chemotherapy Protocols/*pharmacology | 2 | 4.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Tumor Cells, Cultured/drug effects | 4 | 0.0 |
Mitomycin | 14 | 28.0 |
Mitomycins/administration & dosage | 7 | 38.0 |
Mitomycins/*pharmacology | 2 | 50.0 |
Remission Induction | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*adverse effects | 2 | 4.0 |
Anemia, Aplastic/*genetics | 3 | 33.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy | 2 | 7.0 |
Lung Neoplasms/*drug therapy | 2 | 4.0 |
Tegafur/administration & dosage | 2 | 11.0 |
4-Nitroquinoline-1-oxide/pharmacology | 2 | 25.0 |
Alzheimer Disease/*genetics | 2 | 0.0 |
Colonic Polyps/genetics | 2 | 66.0 |
Gardner Syndrome/*genetics | 2 | 66.0 |
Lymphocytes/drug effects/ultrastructure | 2 | 20.0 |
Methylnitronitrosoguanidine/pharmacology | 2 | 8.0 |
*Sister Chromatid Exchange/drug effects | 2 | 50.0 |
*Tobacco Smoke Pollution | 2 | 18.0 |